Obesity Management

On July 27, 2023, Eli Lilly and Company announced topline results of the SURMOUNT-3 and SURMOUNT-4 trials, with both trials achieving all primary endpoints of interest and full results scheduled to be presented later this year.

A new scientific statement indicates lifestyle interventions may change the trajectory of obesity-related cardiovascular risk from onset in childhood to manifestation in adulthood.

The BARI-OPTIMISE randomized clinical trial reports individuals with poor weight loss after metabolic surgery had significantly greater reductions in body weight after treatment with 3.0 mg liraglutide, compared with placebo.

With the popularity of the class skyrocketing, the American Society of Anesthesiologists has released new guidance urging patients to withhold GLP-1 receptor agonist use prior to elective surgeries or procedures based on potential risk of regurgitation and aspiration associated with delayed gastric emptying.

In this MEDcast episode, Diana Isaacs, PharmD, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP-BC, interview Dr Juan Frias to explore the mechanism of GLP-1 and GIP agonists in diabetes and weight management and examine key findings from clinical trials for the latest GLP-1/GIP dual agonist.

In this MEDcast episode, Diana Isaacs, PharmD, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP-BC, interview Dr Juan Frias to explore the mechanism of GLP-1 and GIP agonists in diabetes and weight management and examine key findings from clinical trials for the latest GLP-1/GIP dual agonist.

An analysis of data from nearly 750,000 adolescents from more than 40 countries offers insight into the changing, and possibly inaccurate, perceptions of healthy body weight among younger people since the turn of the century.

Data from a phase 2 substudy of retatrutide indicates use could reduce liver fat content and contribute to resolution of NAFLD in people with NAFLD and obesity.

W. Timothy Garvey, MD, sits down to discuss the results of SURMOUNT-2, the ongoing revolution of antiobesity medications, and why he is concerned over the growing prevalence of online weight loss clinics

Data from a pair of phase 2 trials in patients with overweight/obesity and type 2 diabetes presented at ADA 2023 suggest the GIP/GLP-1/Glucagon agonist retatrutide could provide significant weight loss and glycemic control benefits.

Data from a pair of trials presented at ADA 2023 suggests an upped dose of oral semaglutide could soon be on the horizon, with results supporting use in chronic weight management as well as type 2 diabetes.

At ADA 2023, we sat down with W. Timothy Garvey, MD, to learn more about the safety and efficacy of tirzepatide in the SURMOUNT-2 trial and how the results complement SURMOUNT-1.

Data from SURMOUNT-2 presented at ADA 2023 build on results from the SURMOUNT-1 trial, with results detailing the weight loss achieved with tirzepatide in people with type 2 diabetes and overweight or obesity.

A pair of phase 2 trials presented at ADA 2023 detail the body weight lowering and glycemic control benefits of orforglipron, an oral GLP-1 RA developed by Eli Lilly and Company.

Data from a phase 2 dose-finding trial from ADA 2023 suggests use of survodutide was associated with a mean body weight reduction of 14.9% at 46 weeks, with 67% of people using survodutide 4.8 mg losing 15% or more of their baseline body weight.

To celebrate the 10-year anniversary of the AMA recognizing obesity as a disease, this feature leverages the perspective of key opinion leaders to examine what has changed and what has not since the AMA's declaration in June 2013.

A matched case-control study of nearly 100 women details the reduced effect of anti-obesity medications in those with a history of breast cancer and aromatase inhibitor use.

Based on the results of 2 studies, lower birthweight was associated with younger age, lower prevalence of obesity, and fewer individuals with a family history of T2D.

Research presented at ENDO 2023 suggests a high number of adults in the United States with normal BMI still have obesity.

In this episode of MEDcast, Diana Isaacs and Natalie Bellini interview Dr. Ken Fujioka, an endocrine specialist, to discuss practice guidelines on obesity treatment and the evolution of anti-obesity medications over the last decade.

Data from the COVID-OUT trial suggests use of metformin could reduce a person's risk of developing long COVID by more than 50% relative to placebo therapy, with results also providing insight into the apparent lack of benefit with ivermectin and fluvoxamine.

An analysis of nationwide data in Singapore suggests obesity is set to become the leading metabolic risk factor underlying acute myocardial infarction onset, overtaking hypertension and hyperlipidemia in the coming decades.

The ongoing shortage of GLP-1 receptor agonists, namely semaglutide, has prompted the US Food and Drug Administration to issue a warning to patients and providers related to use of compounded semaglutide.

The changes in sleep quality were notably associated with a higher prevalence of obesity indicators in men following the COVID-19 outbreak.

An analysis of data from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program provides an overview of changing rates of access and utilization of metabolic and bariatric surgery among US youths.